Jump to content

Recommended Posts

Posted

An interesting paper about how pharma companies sneak marketing aspects into reviews and commentaries. Normally the FDA regulates what can be said about a drug in marketing. However in this report at least one company has been shown to circumvent that by ghostwriting articles that are designed to market their products. Needless to say this is an extremely unethical on so many levels (including also unethical treatment of authorship).

 

Link

×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.